Abstract:One persistent dogma from the plain old balloon angioplasty (POBA) era is that glycoprotein IIb/IIIa receptor inhibitors must be given for a minimal amount of time beyond the procedure to maximize their benefit. The hypothesis that mechanical stabilization with a stent might abdicate the need for pharmacologic passivization of the coronary artery after percutaneous coronary intervention (PCI) with intravenous antiplatelet agents, and shorten the hospital course, remained an academic question and no industry interest. With the broadening acceptance of transradial techniques, this question has become clinically relevant. Two hours after the end of a transradial PCI, the sheath has been removed and hemostasis is complete; the patient is ambulatory and is left questioning the need for further hospitalization. Bagur et al. in this issue of the Journal [1] have presented the long-term outcomes of a bolus only abciximab regimen and same-day discharge versus standard therapy trial [2], also known as the EASY Trial, that answers affirmatively to the safety of this approach in transradial patients. When one compares the practice described in this single-center, Canadian trial with the suggested practice outlined in the recent statement published by the Society of Cardiac Intervention and the American College of Cardiology [3] on same-day procedures, it is quite striking the gap that has grown between the practice in the femorally dominated United States and those outside of the United States. The Canadian practice excluded early ST-elevation myocardial infarction and those with ejection fractions below 30%, but otherwise considered most of their clinical patient population for inclusion. This was not an isolated, low-risk, elective population but rather was a real-world experience with many patients having various forms of acute coronary syndromes including those with cardiac marker release. The primary determinant of same day discharge was procedural success and lack of intraprocedural complications. The suggestions of the previously mentioned SCAI/ACC writing group included exclusion of a broad range of patients based on preexisting conditions and characteristics, intraprocedural techniques and events, and subsequent use of glycoprotein IIb/IIIa inhibitors. The differences are noted in Table I and point to a growing chasm between advances in PCI care practiced in parts of the world and those of the United States. Only a small minority of the patients reported in this present Canadian trial would have met criteria as an outpatient under the recent SCAI suggestions. When one considers the minimal penetration of transradial techniques in the United States, American patients can look forward to hospitalizations significantly longer than their foreign counterparts with no apparent benefit. Bagur et al. have added to the growing evidence that the concept of postprocedural pharmacologic passivization popularized in the POBA era plays little role in the mechanically stabilized artery of the present stent era. They also provide support to the evidence that lengths of hospitalization can be further shortened by evolution in procedural techniques such as the widespread adaptation of transradial techniques. In addition, the prognostic risk of bleeding is also once again confirmed in this analysis. Despite having used transradial access and altered pharmocologic therapy that together may have eliminated 2/ 3rd of the expected bleeding, this complication nevertheless continued to remain an independent predictor of death at 3-years postprocedure. Advances are clearly still needed beyond just preventing access site bleeding for better outcome. Further research into the use of prophylactic pharmacologic therapy such as PPI’s to prevent gastrointestinal bleeding [4] or exploring wider use of newer antithrombotic agents such as bivalirudin, which can reduce postprocedural organ bleeding is still needed [5]. Perhaps, it is appropriate to quote Dorothy from the movie The Wizard of Oz, ‘‘There’s no place like

Mentorship: a key to retention and recruitment.

On the Complexity of Some Two-Person Perfect-Information Games

Bioengineering Human Pluripotent Stem Cell-Derived Retinal Organoids and Optic Vesicle-Containing Brain Organoids for Ocular Diseases

Structure of clausindine, a new coumarin fromClausena indica Oliv

The application of retinal organoids in ophthalmic regenerative medicine: A mini-review

Emerging strategies of engineering retinal organoids and organoid-on-a-chip in modeling intraocular drug delivery: Current progress and future perspectives

Organoids and Organ Chips in Ophthalmology

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human Retina-on-a-Chip platform

Inherited Retinal Diseases and Retinal Organoids as Preclinical Cell Models for Inherited Retinal Disease Research

A Focus on Human iPSC-Derived Organoid Models

Retinal organoids: a window into human retinal development

There is no place like home after successful percutaneous coronary intervention

Pluripotent stem cell-derived models of retinal disease: Elucidating pathogenesis, evaluating novel treatments, and estimating toxicity

Application of eye organoids in the study of eye diseases

Drug Discovery Strategies for Inherited Retinal Degenerations

Retinal Diseases: The Next Frontier in Pharmacodelivery

Retina organoids: Window into the biophysics of neuronal systems

Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation

Exploring retinal degenerative diseases through CRISPR-based screening

Design and operation of an extended aeration plant.